Why the study?
Does warfarin reduce thromboembolism compared to acetylsalicylic acid in patients with persistent or permanent atrial fibrillation?
Population
108 patients aged 38 to 78 years old with persistent or permanent atrial fibrillation. 93.5% had coronary…
Comparison
Warfarin vs Acetylsalicylic acid (ASA)
Design
Cohort
Follow-up
1 year
Key result
Warfarin treatment in patients with long-lasting atrial fibrillation resulted in fewer thromboembolic endpoints compared to acetylsalicylic acid (5.6% vs 27.8%) at 1 year follow-up.
Authors
Loading...
May support anticoagulation over aspirin in persistent AF; leaves open randomized confirmation in contemporary cohorts.
Observational (n=108)
Does warfarin reduce thromboembolism compared to acetylsalicylic acid in patients with persistent or permanent atrial fibrillation?
Absolute Event Rate: 5.6% vs 27.8%
The CHA2DS2-VASc score identifies more patients requiring anticoagulation than CHADS2, and warfarin is associated with fewer ischemic strokes than aspirin in patients with persistent or permanent AF.
Kurbanov et al. (2014) conducted an observational in Persistent or permanent atrial fibrillation (n=108). Warfarin vs. Acetylsalicylic acid (ASA) was evaluated on Thromboembolism / ischemic stroke. Warfarin treatment in patients with long-lasting atrial fibrillation resulted in fewer thromboembolic endpoints compared to acetylsalicylic acid (5.6% vs 27.8%) at 1 year follow-up.